<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Repinotan is a highly potent 5-HT1A receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> with strong neuroprotective efficacy in animal models of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and traumatic brain injury </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we characterized the time window for neuroprotective effects of repinotan in animal models </plain></SENT>
<SENT sid="2" pm="."><plain>In the permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model, repinotan showed neuroprotective efficacy when administered as a triple bolus injection (0.3-100 microg/kg) or an intravenous infusion (0.3-100 microg/kg per hour) </plain></SENT>
<SENT sid="3" pm="."><plain>A 73% reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was observed with a 3 microg/kg intravenous bolus, and a 65% reduction was observed with a 3 and 10 microg/kg per hour intravenous infusion </plain></SENT>
<SENT sid="4" pm="."><plain>When delayed until 5 hours after occlusion, repinotan (10 microg/kg per hour) reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 43% </plain></SENT>
<SENT sid="5" pm="."><plain>In the transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model, repinotan (10 microg/kg per hour) administered immediately after occlusion reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 97%, and a delay to 5 hours reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 81% </plain></SENT>
<SENT sid="6" pm="."><plain>In the <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0100309'>subdural hematoma</z:hpo> model, repinotan (3 and 10 microg/kg per hour) reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 65% </plain></SENT>
<SENT sid="7" pm="."><plain>In this model, repinotan (3 microg/kg per hour) administered 5 hours after occlusion reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 54% </plain></SENT>
<SENT sid="8" pm="."><plain>The favorable neuroprotective efficacy, broad dose-response curve, and prolonged therapeutic window observed in <z:hpo ids='HP_0000001'>all</z:hpo> models strongly suggest that repinotan is a promising candidate for treating <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in humans </plain></SENT>
</text></document>